These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 34661668)

  • 1. Use of Tumor Necrosis Factor Inhibitors During the COVID-19 Pandemic-Evidence in Favor of Monotherapy.
    Velloso LA
    JAMA Netw Open; 2021 Oct; 4(10):e2129707. PubMed ID: 34661668
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic.
    Brain O; Satsangi J
    Gastroenterology; 2021 Apr; 160(5):1883-1884. PubMed ID: 32553759
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-TNF Therapy During the SARS-CoV-2 Pandemic: Friend or Foe?
    Levartovsky A; Ben-Horin S
    J Crohns Colitis; 2022 May; 16(4):517-518. PubMed ID: 34626174
    [No Abstract]   [Full Text] [Related]  

  • 4. Should patients stop their biologic treatment during the COVID-19 pandemic.
    Bashyam AM; Feldman SR
    J Dermatolog Treat; 2020 Jun; 31(4):317-318. PubMed ID: 32191143
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.
    Marino A; Romano M; Gattinara M; Cimaz R
    Semin Arthritis Rheum; 2020 Dec; 50(6):1214-1215. PubMed ID: 33059294
    [No Abstract]   [Full Text] [Related]  

  • 6. Ambulatory management of perianal Crohn's disease during the COVID-19 pandemic.
    Divizia A; Sensi B; Sica GS
    Colorectal Dis; 2020 Jun; 22(6):645-646. PubMed ID: 32348620
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters.
    Hung CH; Yang TY; Wei JC
    Aliment Pharmacol Ther; 2022 May; 55(9):1233-1234. PubMed ID: 35429022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].
    Steinchen N; Müller-Ladner U; Lange U
    Z Rheumatol; 2020 Aug; 79(6):574-577. PubMed ID: 32514854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.
    Messina F; Pampaloni F; Piaserico S
    Ann Rheum Dis; 2021 May; 80(5):e79. PubMed ID: 32816688
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina
    Duret PM; Spielmann L; Messer L
    Ann Rheum Dis; 2021 May; 80(5):e80. PubMed ID: 32816687
    [No Abstract]   [Full Text] [Related]  

  • 11. Inflammatory Bowel Disease and COVID-19-"Preventive" Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic.
    Schlabitz F; Teich N; Michl P; Walldorf J
    Inflamm Bowel Dis; 2020 Aug; 26(9):e105-e106. PubMed ID: 32530027
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor necrosis factor inhibitors and methotrexate are associated with decreased COVID-19-related hospitalization: Follow up of "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and methotrexate".
    Cahn RT; Zinn Z; Kolodney MS
    J Am Acad Dermatol; 2023 Jun; 88(6):1385-1386. PubMed ID: 36773822
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic.
    Syed MN; Shah M; Shin DB; Wan MT; Winthrop KL; Gelfand JM
    J Am Acad Dermatol; 2021 Jan; 84(1):161-163. PubMed ID: 32860913
    [No Abstract]   [Full Text] [Related]  

  • 14. Biologics, spondylitis and COVID-19.
    Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
    Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologics in systemic autoimmune diseases during COVID-19 pandemic.
    Annapureddy N; Nalleballe K; Onteddu SR; Sharma R; Sheng S; Kovvuru S; Siddamreddy S; Mandhadi R
    Clin Rheumatol; 2020 Dec; 39(12):3529-3531. PubMed ID: 33011932
    [No Abstract]   [Full Text] [Related]  

  • 16. Aminosalicylates and COVID-19: Facts or Coincidences?
    Magro F; Dias CC; Morato M
    Gastroenterology; 2021 Apr; 160(5):1884-1885. PubMed ID: 32553757
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19.
    Tursi A; Vetrone LM; Papa A
    Inflamm Bowel Dis; 2020 Jun; 26(7):e73. PubMed ID: 32382744
    [No Abstract]   [Full Text] [Related]  

  • 18. Nasoseptal Flap Necrosis After Endoscopic Skull Base Surgery in the Setting of COVID-19 Pandemic.
    Talmor G; Grube JG; Eloy JA; Liu JK; Hsueh WD
    World Neurosurg; 2020 Aug; 140():374-377. PubMed ID: 32479908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
    Bekic D; Belosic Halle Z
    Scand J Gastroenterol; 2021 Jun; 56(6):656-660. PubMed ID: 33765405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists.
    Cappello M; Busacca A; Guida L
    Gastroenterology; 2021 Apr; 160(5):1885-1886. PubMed ID: 32645320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.